Nafoxidine

CAT: 0804-HY-145716-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-145716-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Nafoxidine, a nonsteroidal estrogen antagonist, is shown to possess antitumor activity against breast cancer.
CAS Number
[1845-11-0]
Product Name Alternative
Nafoxidene
UNSPSC
12352005
Hazard Statement
H302+H312
Target
Estrogen Receptor/ERR
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nafoxidine.html
Purity
98.75
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
COC1=CC(CCC(C2=CC=CC=C2)=C3C4=CC=C(OCCN5CCCC5)C=C4)=C3C=C1
Molecular Formula
C29H31NO2
Molecular Weight
425.56
Precautions
H302+H312
References & Citations
[1]Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996;10 (8) :905-912. |[2]De Lorenzo MS, Farina HG, Alonso DF, Gomez DE. Role of protein kinase C-dependent signaling pathways in the antiangiogenic properties of nafoxidine. Anticancer Res. 2004;24 (3a) :1737-1743.|[3]Yaz G, Kabadere S, Oztopçu P, Durmaz R, Uyar R. Comparison of the antiproliferative properties of antiestrogenic drugs (nafoxidine and clomiphene) on glioma cells in vitro. Am J Clin Oncol. 2004;27 (4) :384-388.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName

Popular Products